Logo

Novo Nordisk Reports Improved Results of Oral Semaglutide in PIONEER 9 Study in Patients with Type-2 Diabetes (T2D)

Share this
Novo Nordisk Reports Improved Results of Oral Semaglutide in PIONEER 9 Study in Patients with Type-2 Diabetes (T2D)

Novo Nordisk Reports Improved Results of Oral Semaglutide in PIONEER 9 Study in Patients with Type-2 Diabetes (T2D)

Shots:
  • The P-IIIa PIONEER 9 trial involves assessing of Oral Semaglutide (3- 7-14 mg- qd) vs Victoza (0.9 mg liraglutide) vs PBO in 243 Japanese adults in ratio (1:1:1:1:1) with T2D treated with diet and exercise alone or in addition to an oral anti-diabetic drug as monothx
  • Results: reduction in HbA1c @26 wks. (1.1%- 1.5% -1.7% vs 1.4% vs 0.1%); greater reductions in HbA1c @52 wks. (0.9%- 1.3%- 1.5% vs 1.1% vs 0.5%); Achieve target treatment (50%- 67% -80% vs 49% vs 12%); reduction in body weight (0.0- 0.6- 2.8 vs 0.4 vs 1.0 kg); safe & well-tolerated
  • Semaglutide is an oral qd GLP-1 analogue indicated for reduction in cardiovascular risk and death in T2D patients
Click here to read full press release/ article | Ref: Novo Nordisk | Image:Borsen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

We Have a Viewership of 1,00,000 + Views

Join the PharmaShot Family